on the behalf of the PRIORITY Study Group 2023, ' Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria – A post-hoc analysis of the PRIORITY randomized clinical trial ', Journal of Diabetes and its Complications, vol. 37, no. 4, 108433 . https://doi.org/10.1016/j.jdiacomp.2023.108433 JOURNAL OF DIABETES AND ITS COMPLICATIONS, 37(4):108433. ELSEVIER SCIENCE INC Journal of Diabetes and its Complications, 37(4):108433. Elsevier Inc.
Diabetes, obesity and metabolism 21 (2019): 1177–1190. doi:10.1111/dom.13639 info:cnr-pdr/source/autori:Piero Ruggenenti; Matias Trillini; Drazenka P. Barlovic; Monica Cortinovis; Antonio Pisani; Aneliya Parvanova; Ilian Iliev; Barbara Ruggiero; Stefano Rota; Maria C Aparicio; Annalisa Perna; Francesco Peraro; Olimpia Diadei; Flavio Gaspari; Fabiola Carrara; Nadia Stucchi; Davide Martinetti; Andrej Janez; Nadah Gregoric; Eleonora Riccio; Antonio C. Bossi; Roberto Trevisan; Paolo Manunta; Giovanni Battaglia; Salvatore David; Filippo Aucella; Antonio Belviso,; Andrea Satta; Giuseppe Remuzzi/titolo:Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial/doi:10.1111%2Fdom.13639/rivista:Diabetes, obesity and metabolism (Print)/anno:2019/pagina_da:1177/pagina_a:1190/intervallo_pagine:1177–1190/volume:21
Lancet Diabetes & Endocrinology, 8(4), 301-312. ELSEVIER SCIENCE INC Tofte, N, Lindhardt, M, Adamova, K, Bakker, S J L, Beige, J, Beulens, J W J, Birkenfeld, A L, Currie, G, Dimos, I, Francová, L, Frimodt-Møller, M, Girman, P, Göke, R, Havrdova, T, Heerspink, H J L, Kooy, A, Laverman, G D, Mischak, H, Navis, G, Nijpels, G, Noutsou, M, Ortiz, A, Parvanova, A, Persson, F, Petrie, J R, Ruggenenti, P L, Rutters, F, Rychlík, I, Siwy, J, Spasovski, G, Speeckaert, M, Trillini, M, Zürbig, P, von der Leyen, H, Rossing, P, PRIORITY investigators & Nijpels, MGAAM 2020, ' Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY) : a prospective observational study and embedded randomised placebo-controlled trial ', The Lancet Diabetes and Endocrinology, vol. 8, no. 4, pp. 301-312 . https://doi.org/10.1016/S2213-8587(20)30026-7 Ann Transl Med The Lancet Diabetes and Endocrinology, 8(4), 301-312. Elsevier BV Lancet Diabet. Endocrinol. 8, 301-312 (2020)